Opinion of the Transparency Council – venlafaxine
At its meeting of 16 January 2023, the Transparency Council adopted Opinion No. 5/2023 on the inclusion in the reimbursement procedure of medicines containing the active substance venlafaxine for selected off-label indications.
Publication on the list of opinions on active substances for off-label indications